PMID- 20489656
OWN - NLM
STAT- MEDLINE
DCOM- 20101223
LR  - 20181201
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Linking)
VI  - 56
IP  - 2
DP  - 2010 Aug
TI  - Tongxinluo inhibits oxidized low-density lipoprotein-induced maturation of human 
      dendritic cells via activating peroxisome proliferator-activated receptor gamma 
      pathway.
PG  - 177-83
LID - 10.1097/FJC.0b013e3181e5f0f8 [doi]
AB  - TongXinLuo (TXL) is a traditional Chinese herbal medicine with multiple 
      vasoprotective activities. Dendritic cells (DCs) play an active role in the 
      immunological processes related to atherosclerosis. The purpose of this study was 
      to determine the effect and possible mechanisms of TXL on oxidized low-density 
      lipoprotein (OX-LDL)-induced maturation and immune function of DCs. Human 
      monocyte-derived DCs were incubated with TXL or ciglitazone and were subsequently 
      stimulated with OX-LDL to induce maturation. Similar to ciglitazone, a peroxisome 
      proliferator-activated receptor (PPAR) gamma agonist, TXL could significantly 
      reduce the maturation-associated markers induced by OX-LDL, such as CD40, CD86, 
      CD1a, and human leukocyte antigen-DR; improved the endocytotic function; and 
      decreased secretions of cytokine interleukin-12 and tumor necrosis factor alpha. 
      These inhibitory effects of TXL could be partly reversed by silencing the 
      expression of PPAR gamma in DCs. In conclusion, TXL could inhibit OX-LDL-induced 
      maturation of DCs through activating PPAR gamma pathway.
FAU - Su, Wei
AU  - Su W
AD  - Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan 
      University, Shanghai, China.
FAU - Sun, Aijun
AU  - Sun A
FAU - Xu, Danling
AU  - Xu D
FAU - Zhang, Hongqi
AU  - Zhang H
FAU - Yang, Lin
AU  - Yang L
FAU - Yuan, Lingyan
AU  - Yuan L
FAU - Jia, Jianguo
AU  - Jia J
FAU - Zou, Yunzeng
AU  - Zou Y
FAU - Wu, Yiling
AU  - Wu Y
FAU - Wang, Keqiang
AU  - Wang K
FAU - Ge, Junbo
AU  - Ge J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Antigens, CD1)
RN  - 0 (B7-2 Antigen)
RN  - 0 (CD1a antigen)
RN  - 0 (CD40 Antigens)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (PPAR gamma)
RN  - 0 (Thiazolidinediones)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (oxidized low density lipoprotein)
RN  - 0 (tongxinluo)
RN  - 187348-17-0 (Interleukin-12)
RN  - U8QXS1WU8G (ciglitazone)
SB  - IM
MH  - Antigens, CD1/metabolism
MH  - B7-2 Antigen/metabolism
MH  - CD40 Antigens/metabolism
MH  - Cells, Cultured
MH  - Dendritic Cells/*drug effects/immunology/metabolism
MH  - Drugs, Chinese Herbal/*pharmacology
MH  - Endocytosis
MH  - HLA-DR Antigens/immunology/metabolism
MH  - Humans
MH  - Interleukin-12/antagonists & inhibitors/metabolism
MH  - Lipoproteins, LDL/*antagonists & inhibitors/physiology
MH  - PPAR gamma/*agonists/metabolism
MH  - Thiazolidinediones/pharmacology
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors/metabolism
EDAT- 2010/05/22 06:00
MHDA- 2010/12/25 06:00
CRDT- 2010/05/22 06:00
PHST- 2010/05/22 06:00 [entrez]
PHST- 2010/05/22 06:00 [pubmed]
PHST- 2010/12/25 06:00 [medline]
AID - 10.1097/FJC.0b013e3181e5f0f8 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2010 Aug;56(2):177-83. doi: 10.1097/FJC.0b013e3181e5f0f8.